These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 21767908)
1. Targeting apoptosis proteins in hematological malignancies. Droin N; Guéry L; Benikhlef N; Solary E Cancer Lett; 2013 May; 332(2):325-34. PubMed ID: 21767908 [TBL] [Abstract][Full Text] [Related]
2. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio. Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells. Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477 [TBL] [Abstract][Full Text] [Related]
4. Messengers of cell death: apoptotic signaling in health and disease. Rossi D; Gaidano G Haematologica; 2003 Feb; 88(2):212-8. PubMed ID: 12604411 [TBL] [Abstract][Full Text] [Related]
5. TRAIL/TRAIL-R in hematologic malignancies. Testa U J Cell Biochem; 2010 May; 110(1):21-34. PubMed ID: 20336667 [TBL] [Abstract][Full Text] [Related]
6. In bcr-abl-positive myeloid cells resistant to conventional chemotherapeutic agents, expression of Par-4 increases sensitivity to imatinib (STI571) and histone deacetylase-inhibitors. Brieger A; Boehrer S; Schaaf S; Nowak D; Ruthardt M; Kim SZ; Atadja P; Hoelzer D; Mitrou PS; Weidmann E; Chow KU Biochem Pharmacol; 2004 Jul; 68(1):85-93. PubMed ID: 15183120 [TBL] [Abstract][Full Text] [Related]
7. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347 [TBL] [Abstract][Full Text] [Related]
8. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094 [TBL] [Abstract][Full Text] [Related]
9. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) promotes mitochondrial dysfunction and apoptosis induced by 7-hydroxystaurosporine and mitogen-activated protein kinase kinase inhibitors in human leukemia cells that ectopically express Bcl-2 and Bcl-xL. Dai Y; Dent P; Grant S Mol Pharmacol; 2003 Dec; 64(6):1402-9. PubMed ID: 14645670 [TBL] [Abstract][Full Text] [Related]
11. Synergistic induction of apoptosis in breast cancer cells by cotreatment with butyrate and TNF-alpha, TRAIL, or anti-Fas agonist antibody involves enhancement of death receptors' signaling and requires P21(waf1). Chopin V; Slomianny C; Hondermarck H; Le Bourhis X Exp Cell Res; 2004 Aug; 298(2):560-73. PubMed ID: 15265702 [TBL] [Abstract][Full Text] [Related]
12. Interactive effects of histone deacetylase inhibitors and TRAIL on apoptosis in human leukemia cells: involvement of both death receptor and mitochondrial pathways. Shankar S; Singh TR; Fandy TE; Luetrakul T; Ross DD; Srivastava RK Int J Mol Med; 2005 Dec; 16(6):1125-38. PubMed ID: 16273296 [TBL] [Abstract][Full Text] [Related]
13. Drug-mediated sensitization to TRAIL-induced apoptosis in caspase-8-complemented neuroblastoma cells proceeds via activation of intrinsic and extrinsic pathways and caspase-dependent cleavage of XIAP, Bcl-xL and RIP. Mühlethaler-Mottet A; Bourloud KB; Auderset K; Joseph JM; Gross N Oncogene; 2004 Jul; 23(32):5415-25. PubMed ID: 15094781 [TBL] [Abstract][Full Text] [Related]
14. Sensitization of melanoma cells for death ligand-induced apoptosis by an indirubin derivative--Enhancement of both extrinsic and intrinsic apoptosis pathways. Berger A; Quast SA; Plötz M; Hein M; Kunz M; Langer P; Eberle J Biochem Pharmacol; 2011 Jan; 81(1):71-81. PubMed ID: 20858462 [TBL] [Abstract][Full Text] [Related]
15. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
16. Reprogramming cell death: BCL2 family inhibition in hematological malignancies. Scarfò L; Ghia P Immunol Lett; 2013; 155(1-2):36-9. PubMed ID: 24095849 [TBL] [Abstract][Full Text] [Related]
17. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Bai J; Sui J; Demirjian A; Vollmer CM; Marasco W; Callery MP Cancer Res; 2005 Mar; 65(6):2344-52. PubMed ID: 15781649 [TBL] [Abstract][Full Text] [Related]
18. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players. Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419 [TBL] [Abstract][Full Text] [Related]
19. Redistribution of CD95, DR4 and DR5 in rafts accounts for the synergistic toxicity of resveratrol and death receptor ligands in colon carcinoma cells. Delmas D; Rébé C; Micheau O; Athias A; Gambert P; Grazide S; Laurent G; Latruffe N; Solary E Oncogene; 2004 Nov; 23(55):8979-86. PubMed ID: 15480430 [TBL] [Abstract][Full Text] [Related]
20. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]